Warner Weston Biddle - Sep 16, 2024 Form 4 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Role
Chief Executive Officer, Director
Signature
By: /s/ Ryan Jones, as Attorney-in-Fact
Stock symbol
KYTX
Transactions as of
Sep 16, 2024
Transactions value $
$0
Form type
4
Date filed
9/18/2024, 09:18 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYTX Stock Option (right to buy) Award $0 +2.58M $0.00 2.58M Sep 16, 2024 Common Stock 2.58M $6.89 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4th of the shares subject to the option shall vest on September 16, 2025, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.